The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin

Inclusion Criteria: * 145 mmHg ≤ msSBP ≤ 190 mmHg * Triglycerides \< 500 mg/dL * LDL-C ≤ 250 mg/dL Exclusion Criteria: * sSBP ≥ 20mmHg and sDBP ≥ 10mmHg * symptomatic orthostatic hypotension and secondary/iatrogenic hypertension and dyslipidemia * history of moderate to severe cerebral ischemia, cerebral hemorrhage, transient ischemic attack, myocardial infarction, or unstable angina in the past 6 months; severe heart failure (New York Heart Association functional class III and IV) * hypersensitivity to telmisartan or rosuvastatin * history of angioedema after treatment with angiotensin-converting enzyme inhibitors or ARBs; creatinine phosphokinase levels ≥3 times the upper limit of normal * estimated glomerular filtration rate ≤30 mL/min; aspartate aminotransferase and alanine aminotransferase levels ≥3 times the upper limit of normal * potassium levels \>5.5 mmol/L; or any diseases that could affect the results of the study.